Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘MIBC’

Strategic intelligence report on bladder cancer

In looking at the new developments in urothelial carcinomas presented at ASCO GU in San Francisco last week, the biggest risk facing novel bladder cancer programmes right now is strategic rather than clinical.

Bladder cancer

The field has clearly been moving of late.

Meanwhile a number of molecules currently in phase 2 development could soon reach phase 3, only to find the control arm has changed, the endpoints have shifted, and the patients they’ll enroll may look nothing like the population the drug was originally intended for.

Loss of relevancy is a real threat in this kind of situation.

Here’s what you need to know…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

New developments in Genitourinary cancers

San Francisco!

San Francisco – It’s time to switch horses for some the latest conference coverage and explore some important new findings emerging from the genitourinary world of bladder, prostate, and renal cell cancers at the ASCOGU specialist meeting held late last week.

Not that many years ago, much of this niche was dominated by numerous updates in prostate cancer, with little good cheer to write about on the other two cancers – how things have changed in such a short time!

This year there’s plenty going on in all three categories, I’m pleased to say.

Here we focus on several important trials or targets and explain why they matter and what’s significant about the findings…

Some of the agents or trials selected here are likely to receive more attention going forward as more data become available, so it behooves us to set the scene now.

To learn more from our oncology coverage and get a heads up on our latest analysis and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!